HARTALEGA HOLDINGS |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.67 MYR | 0.00% |
|
+1.52% | -1.11% |
| Mar. 12 | Malaysian Stocks Maintain Four-Day Winning Streak; Kobay Technology's Shares Rally 12% | MT |
| Feb. 07 | Hartalega Sets Up Share Grant Scheme | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 149.5 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.79 times its current sales, is high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -1.11% | 1.91B | B | ||
| +11.84% | 27.79B | B+ | ||
| -32.98% | 2.98B | B- | ||
| -15.97% | 2.52B | C+ | ||
| +11.90% | 2.34B | - | A- | |
| -7.78% | 1.39B | B | ||
| -0.38% | 1.27B | - | ||
| +4.01% | 1.13B | - | ||
| +13.51% | 1.12B | C | ||
| -2.06% | 1.02B | B |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- HARTA Stock
- Ratings Hartalega Holdings
